

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-12. (canceled).

13. (previously presented): A method for treatment of cancer, wherein a pharmaceutically effective amount of completely human anti-PD-1 antibody is parenterally administered to a subject with cancer in which PD-L1 or PD-L2 is over-expressed, postoperatively.

14. (original) The method for treatment of cancer according to claim 13, which suppresses cancer metastasis.

15 - 35 (canceled).

36. (currently amended): ~~The~~A method for enhancing cytotoxic T cell activity toward PD-L1 or PD-L2 over-expressing cancer cells ~~according to claim 34, which comprises administering a pharmaceutically effective amount of a completely human anti-PD-1 antibody to a subject with cancer in which PD-L1 or PD-L2 is over-expressed,~~ wherein the effective dose of the completely human anti-PD-1 antibody is administered parenterally and postoperatively.

37. (new): The method of claim 36, whereby cancer metastasis is suppressed.